Bridging Nonconsecutive Esketamine Weeks with Bupropion and Over-the-Counter Dextromethorphan
Psychopharmacology Bulletin · 2026-10-29 · 56 (4) · 169-172
DOI: 10.64719/pb.21636 ↗Abstract
Frequent clinic visits required for maintenance intranasal (IN) esketamine therapy can limit treatment feasibility. Our case presents a 52-year-old woman with treatment-resistant depression (TRD) and bipolar II disorder (BD-II) who achieved sustained remission with weekly esketamine, but consistently experienced relapse of depressive symptoms when treatment intervals extended beyond 10 days. Her Patient Health Questionnaire-9 (PHQ-9) score decreased from 27 at baseline to 4 (±1) during maintenance treatment; however, with even a single delayed session, her PHQ-9 score could increase by as many as 8 points (from 4 to 12). To prevent relapse when she could not receive esketamine weekly, she began taking over-the-counter (OTC) dextromethorphan (DXM) and continued bupropion extended-release (XL), which she started prior to esketamine treatment. With 45 mg twice daily (BID) DXM and 450 mg daily bupropion XL, she was able to tolerate every-other-week administration of esketamine without depressive relapse. DXM and esketamine are both believed to function via antagonism of N-methyl-D-aspartate (NMDA) receptors. Bupropion is a competitive inhibitor of cytochrome P450 2D6 (CYP2D6), which is involved in the metabolism of DXM and maintenance of serum DXM concentration.1 As our patient was already taking bupropion XL, beginning OTC DXM was a low-cost option that we hoped would prevent relapse via continued NMDA antagonism in esketamine’s absence. To date, she is stable on a regimen of esketamine administration every 14 days, followed by 1 week of BID OTC DXM, to bridge esketamine doses and maintain NMDA antagonism, without return of depressive symptoms.
EUVIMED